Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Numab Therapeutics AG
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Jan 11, 2025
Finance
Pre-JPM venture bonanza
Fourteen companies announce series A rounds ahead of conference, six with over $100 million
BioCentury | Nov 19, 2024
Deals
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo
BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more
BioCentury | Jun 4, 2024
Deals
Biotech M&A, Biosecure expands & ASCO update: a BioCentury podcast
An M&A quartet. House China committee’s new focus. Colorectal cancer immunotherapies.
BioCentury | May 29, 2024
Deals
Deals Report: Three $1B+ takeouts highlight demand in immunology, renal
Plus: Takeda-Degron to develop molecular glue degraders; Lilly-Aktis collaborate on radiopharmaceuticals; and more
BioCentury | May 28, 2024
Deals
J&J adds bispecific for atopic dermatitis via deal with Numab
Ten-figure M&A transaction with Swiss antibody company gives the pharma an immunology asset targeting IL-4RA and IL-31; builds on Proteologix deal
BioCentury | Feb 21, 2024
Deals
Deal report: Astellas taps Kelonia for CAR Ts, Aurinia fails to find buyer, and more
Plus: Xoma-Kinnate, Almirall-Novo, Intellia-ReCode, Roche-Repare and more
BioCentury | Jul 22, 2023
Deals
July 21 Quick Takes: Gilead drops CD47 lead indication due to futility
Plus: Turnstone shares sag after upsized IPO, Idorsia unveils cost-cutting plan, and updates from ADC, the FTC, TVM, Verrica and more
BioCentury | Apr 1, 2022
Finance
March 31 Quick Takes: V-Bio, HealthQuad close venture funds
Plus CDMO Abzena raises $65M, Clovis meets in ovarian cancer, InflaRx misses in COVID, FDA updates COVID EUA guidance and more
BioCentury | Dec 22, 2021
Product Development
PD-1’s new narrative – a bonanza of innovation
Half the field is stuck in first gear, but a wealth of bispecifics, novel technologies are bringing new energy
Items per page:
1 - 10 of 20